Colospan Ltd. (&#34;Colospan&#34;) provides Galmed Pharmaceuticals Ltd. (&#34;Galmed&#34;) (NASDAQ:GLMD) with a commercially ready product in the EU/Israel (CE marked under MDR) with a dedicated OPS code to accelerate

<p xmlns="http://www.w3.org/1999/xhtml">Colospan Ltd. (&#34;Colospan&#34;) provides Galmed Pharmaceuticals Ltd. (&#34;Galmed&#34;) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/GLMD">GLMD</a>) with a commercially ready product in the EU/Israel (CE marked under MDR) with a dedicated OPS code to accelerate reimbursement in Germany</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Strategic and Financial Highlights<br xmlns="http://www.w3.org/1999/xhtml"></br></b></p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Restructured Anti-Dilutive Financial Terms:</b> To diminish the dilutive event on GLMD&#39;s existing shareholders, Galmed and Colospan agreed that in lieu of issuing $2.0 million in Galmed ordinary shares at closing, the cash payment shall be increased by $800K. The remaining balance has been structured as a transparent, risk-mitigated earnout capped at $2.0 million, commencing in Q3 2027. This single-digit percentage earnout on net sales revenues is tied to clear performance tiers: a 7% payout on net sales revenue over $5.0 million (Tier 1), escalating to 9% for net sales revenue over $12.0 million (Tier 2). In addition, the parties agreed to an acceleration of the earnout upon the earlier of a strategic transaction involving substantially all of the acquired business or related intellectual property of Colospan, or Galmed raising at least $17.5 million in aggregate gross proceeds through equity financings.</p><ul xmlns="http://www.w3.org/1999/xhtml" type="disc"><li xmlns="http://www.w3.org/1999/xhtml">Galmed is laying the groundwork for a pan-European launch of CG-100, a less invasive intraluminal bypass device designed to protect colorectal anastomoses and reduce the need for diverting stomas.</li><li xmlns="http://www.w3.org/1999/xhtml">CG-100 benefits from strong safety and efficacy clinical data based on 4 clinical trials conducted in Europe between 2014 and 2024.</li><li xmlns="http://www.w3.org/1999/xhtml">In addition to generating top-line revenue already in 2026, &#34;real-life&#34; data from patients using CG-100 is planned to be submitted to the FDA to support Colospan&#39; s Pivotal study</li><li xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Strategic Synergy:</b> Establishing a unified GI platform by leveraging drug development expertise with medical device commercialization.</li></ul><p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">RAMAT GAN, Israel</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">June 22, 2026</span> /PRNewswire/ -- Galmed today announces that following a restructuring of the acquisition terms, it consummated the acquisition of Colospan a commercial-stage medical device company that has developed a clinically differentiated solution to one of <b xmlns="http://www.w3.org/1999/xhtml">colorectal surgery&#39;s most pressing problems: anastomotic leak</b> complications and the diverting stomas used to manage them.</p>
<div xmlns="http://www.w3.org/1999/xhtml" id="prni_dvprnejpg510eleft" dir="ltr" style="width: 100%; text-align: left;"><img xmlns="http://www.w3.org/1999/xhtml" id="prnejpg510eleft" title="Galmed Pharmaceuticals Logo" src="https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg" alt="Galmed Pharmaceuticals Logo" align="middle"></img></div><p xmlns="http://www.w3.org/1999/xhtml">As a result of the acquisition, Colospan became a wholly owned subsidiary of Galmed. The acquisition of Colospan gives Galmed a commercial-ready product in the EU/Israel (CE marked under MDR and AMAR approved in Israel) with a dedicated OPS code (5-46b.2) in Germany, potentially allowing Galmed to potentially generate top-line revenue faster than traditional drug pipelines.</p><p xmlns="http://www.w3.org/1999/xhtml">To date, 97 patients have been treated with the CG-100 worldwide across four clinical trials in Europe, and Israel, (not including the US pivotal trial which is ongoing). Results of these trials demonstrated that 90% of patients treated with the CG-100 avoided stoma creation. No device migration was observed in any patient, and 100% patient tolerability was achieved. Safety data for CG-100 showed 0% mortality (compared to 1.3% in patients with Stoma), 3% anastomotic leak rate (compared to 6.3% in patients with stoma), and 3% device-related adverse events graded Clavien-Dindo 3–5 (compared to 22.1% in patients with stoma). None of the Colospan&#39;s patients necessitated a permanent stoma as opposed to 23.5% in the patients with a temporary stoma.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Strategic Synergy</b></p><p xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">&#34;By combining resources, Galmed plans to deliver a clinically compelling and economically meaningful tool to reshape the standard of care for colorectal resection patients worldwide,</i>&#34; said<i xmlns="http://www.w3.org/1999/xhtml"> <b xmlns="http://www.w3.org/1999/xhtml">Allen Baharaff, Co-founder and Chief Executive Officer of Galmed</b>. &#34;The acquisition of Colospan aligns with our long-term strategic focus which remains the GI space. We strongly believe that CG-100 together with the advancement of our Ph 3 ready lead drug candidate, Aramchol, for GI related oncology indications will establish Galmed as a specialty GI medtech and biopharmaceutical platform.&#34;</i></p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">Mr. Baharaff continued</i></b><i xmlns="http://www.w3.org/1999/xhtml">: &#34;While the original terms of the acquisition contained an immediate dilutive payment in ordinary shares of $2.0 million, in order to prevent the immediate dilutive impact on Galmed shareholders, we worked together with Colospan&#39;s Board and lead investors to reach a preferred agreement: an additional cash payment of $800K (made possible by our solid cash balance of $15.6 million as of March 31, 2026) and a transparent, risk-mitigated earnout of $2.0 million on net sales, commencing in Q3 2027.&#34;</i></p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">ABOUT GALMED PHARMACEUTICALS LTD.</b></p><p xmlns="http://www.w3.org/1999/xhtml">Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/GLMD">GLMD</a>) is an Israel-based biopharmaceutical company headquartered in Ramat Gan, with a growing focus on gastrointestinal and oncological innovation. Galmed&#39;s flagship asset, Aramchol, is a first-in-class synthetic fatty acid-bile acid conjugate molecule under evaluation across liver disease and oncological indications, including GI cancers. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.galmedpharma.com/" target="_blank" rel="nofollow">www.galmedpharma.com</a>.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">ABOUT COLOSPAN LTD.</b></p><p xmlns="http://www.w3.org/1999/xhtml">Colospan Ltd. is a commercial-stage medical device company headquartered in Kfar Saba, Israel. Its flagship product, CG-100, is an intraluminal bypass device designed to protect colorectal anastomoses and reduce the need for diverting stomas, offering a less invasive alternative to standard surgical practice. CG-100 was granted FDA Breakthrough Device Designation, is CE marked under the EU Medical Device Regulation, and is approved for investigational use in the United States under an FDA approved IDE. The device is not approved for commercial use in the US. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.colospan.com/" target="_blank" rel="nofollow">www.colospan.com</a>.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">FORWARD-LOOKING STATEMENTS</b></p><p xmlns="http://www.w3.org/1999/xhtml">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to anticipated or expected events, activities, trends, or results as of the date they are made, including statements regarding the expected benefits of the acquisition. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those expressed or implied.</p><p xmlns="http://www.w3.org/1999/xhtml">Factors that could cause differences include, but are not limited to Galmed&#39;s inability to recognize the anticipated benefits of the acquisition of Colospan; expectations with respect to future performance and growth of Colospan; Galmed and Colospan&#39;s ability to execute their business plans and strategy and to receive regulatory approvals; potential litigation involving the parties; changes in domestic and foreign business, market, financial, political and legal conditions; market adoption and pricing barriers; intellectual property enforcement or infringement claims; manufacturing and supply chain constraints; intense industry competition; the ability to maintain listing on the Nasdaq Capital Market; geopolitical events, including the security situation in Israel; regulatory changes; access to additional financing; and other risks and uncertainties indicated from time to time in filings with the SEC by Galmed Additional risks relating to Colospan&#39;s product and its strategy are detailed in a report on Form 6-K filed by Galmed with the SEC on June 8, 2026 and risks associated with Galmed are detailed in Galmed&#39;s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on March 31, 2026 under the heading &#34;Risk Factors.&#34; Galmed undertakes no obligation to publicly update or revise any forward-looking statements to reflect new information, change in expectations, subsequent events, or otherwise, except as required by law. </p><p xmlns="http://www.w3.org/1999/xhtml"> Logo: <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg" target="_blank" rel="nofollow">https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg</a></p><p xmlns="http://www.w3.org/1999/xhtml"> </p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=IO88572&amp;sd=2026-06-22"></img> View original content:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-ltd-announces-restructured-acquisition-terms-for-colospan-ltd-prioritizing-cg-100-european-commercialization-and-shareholder-value-protection-and-consummation-of-acquisition-302806225.html" target="_blank">https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-ltd-announces-restructured-acquisition-terms-for-colospan-ltd-prioritizing-cg-100-european-commercialization-and-shareholder-value-protection-and-consummation-of-acquisition-302806225.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE Galmed Pharmaceuticals Ltd.</p>

GLMD

Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition

Galmed restructures Colospan deal to accelerate CG-100 Europe and value

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Colospan Ltd. (&amp;#34;Colospan&amp;#34;) provides Galmed Pharmaceuticals Ltd. (&amp;#34;Galmed&amp;#34;) (NASDAQ:GLMD) with a commercially ready product in the EU/Israel (CE marked under MDR) with a dedicated OPS code to accelerate</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Galmed Pharmaceuticals updated the Colospan acquisition terms, shifting to $0.8 million cash and a capped $2.0 million earnout starting in Q3 2027, reducing immediate dilution. The deal supports a pan-European launch of CG-100, a minimally invasive device with CE MDR clearance and a dedicated German reimbursement OPS code, with 97 patients treated and strong safety data across four trials. Galmed also plans to submit real-world CG-100 data to the FDA to support its pivotal study, potentially accelerating near-term revenue in 2026-27.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Galmed restructures Colospan deal to reduce GLMD dilution; cash up by $0.8M and earnout capped at $2.0M.</li><li>CG-100 poised for EU/Israel rollout; Germany reimbursement code may speed revenue.</li><li>CG-100 clinical data: 97 patients across 4 trials; 90% avoided stoma with strong safety.</li><li>Real-world CG-100 data planned to support FDA pivotal study.</li><li>Strategic GI platform synergy: combining Colospan device with Galmed’s GI/oncology focus.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Galmed Pharmaceuticals Ltd. (GLMD)</strong>: Restructures Colospan deal to reduce immediate dilution; gains potential revenue upside from CG-100 and GI platform synergy.</li><li><strong>Colospan Ltd. (COLSPAN (private))</strong>: Commercial-stage medical device; CG-100 provides a commercial-ready EU/Israel product with Germany reimbursement potential.</li></ul>
  </section>

  <section data-block="category">
    <h3>M&amp;A</h3>
    <p>Category: M&amp;A. The press release centers on restructuring an acquisition terms to preserve shareholder value while outlining CG-100 commercialization strategy and platform synergy within GI space.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Dilution risk reduced: $0.8M cash, $2.0M earnout lowers immediate share issuance.</li><li>Germany OPS code 5-46b.2 could expedite reimbursement and rollout.</li><li>EU/Israel CE MDR clearance underpins near-term CG-100 commercialization.</li><li>US pivotal trial and FDA data plans may catalyze further upside.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>$0.8 million cash payment added; $2.0 million earnout cap; replaces $2.0 million in Galmed ordinary shares.</li><li>Earnout starts Q3 2027; 7% of net sales over $5.0M (Tier 1) and 9% over $12.0M (Tier 2).</li><li>Earnout accelerates on strategic transaction or if Galmed raises $17.5M gross via equity financings.</li><li>CG-100: CE marked under MDR; AMAR approved in Israel; Germany OPS code 5-46b.2.</li><li>CG-100 has treated 97 patients across 4 trials; 90% avoided stoma; 0% mortality.</li><li>CG-100 safety: 3% anastomotic leak; 3% device-related AEs; none required permanent stoma.</li><li>US pivotal trial ongoing; real-world CG-100 data planned for FDA submission.</li><li>Galmed cash balance: $15.6 million as of 3/31/2026; Colospan is now a wholly owned subsidiary.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish on GLMD as CG-100 Europe commercialization accelerates and dilution is mitigated, with revenue potential starting in 2026.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml">Colospan Ltd. (&#34;Colospan&#34;) provides Galmed Pharmaceuticals Ltd. (&#34;Galmed&#34;) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/GLMD">GLMD</a>) with a commercially ready product in the EU/Israel (CE marked under MDR) with a dedicated OPS code to accelerate reimbursement in Germany</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Strategic and Financial Highlights<br xmlns="http://www.w3.org/1999/xhtml"></br></b></p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Restructured Anti-Dilutive Financial Terms:</b> To diminish the dilutive event on GLMD&#39;s existing shareholders, Galmed and Colospan agreed that in lieu of issuing $2.0 million in Galmed ordinary shares at closing, the cash payment shall be increased by $800K. The remaining balance has been structured as a transparent, risk-mitigated earnout capped at $2.0 million, commencing in Q3 2027. This single-digit percentage earnout on net sales revenues is tied to clear performance tiers: a 7% payout on net sales revenue over $5.0 million (Tier 1), escalating to 9% for net sales revenue over $12.0 million (Tier 2). In addition, the parties agreed to an acceleration of the earnout upon the earlier of a strategic transaction involving substantially all of the acquired business or related intellectual property of Colospan, or Galmed raising at least $17.5 million in aggregate gross proceeds through equity financings.</p><ul xmlns="http://www.w3.org/1999/xhtml" type="disc"><li xmlns="http://www.w3.org/1999/xhtml">Galmed is laying the groundwork for a pan-European launch of CG-100, a less invasive intraluminal bypass device designed to protect colorectal anastomoses and reduce the need for diverting stomas.</li><li xmlns="http://www.w3.org/1999/xhtml">CG-100 benefits from strong safety and efficacy clinical data based on 4 clinical trials conducted in Europe between 2014 and 2024.</li><li xmlns="http://www.w3.org/1999/xhtml">In addition to generating top-line revenue already in 2026, &#34;real-life&#34; data from patients using CG-100 is planned to be submitted to the FDA to support Colospan&#39; s Pivotal study</li><li xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Strategic Synergy:</b> Establishing a unified GI platform by leveraging drug development expertise with medical device commercialization.</li></ul><p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">RAMAT GAN, Israel</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">June 22, 2026</span> /PRNewswire/ -- Galmed today announces that following a restructuring of the acquisition terms, it consummated the acquisition of Colospan a commercial-stage medical device company that has developed a clinically differentiated solution to one of <b xmlns="http://www.w3.org/1999/xhtml">colorectal surgery&#39;s most pressing problems: anastomotic leak</b> complications and the diverting stomas used to manage them.</p>
<div xmlns="http://www.w3.org/1999/xhtml" id="prni_dvprnejpg510eleft" dir="ltr" style="width: 100%; text-align: left;"><img xmlns="http://www.w3.org/1999/xhtml" id="prnejpg510eleft" title="Galmed Pharmaceuticals Logo" src="https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg" alt="Galmed Pharmaceuticals Logo" align="middle"></img></div><p xmlns="http://www.w3.org/1999/xhtml">As a result of the acquisition, Colospan became a wholly owned subsidiary of Galmed. The acquisition of Colospan gives Galmed a commercial-ready product in the EU/Israel (CE marked under MDR and AMAR approved in Israel) with a dedicated OPS code (5-46b.2) in Germany, potentially allowing Galmed to potentially generate top-line revenue faster than traditional drug pipelines.</p><p xmlns="http://www.w3.org/1999/xhtml">To date, 97 patients have been treated with the CG-100 worldwide across four clinical trials in Europe, and Israel, (not including the US pivotal trial which is ongoing). Results of these trials demonstrated that 90% of patients treated with the CG-100 avoided stoma creation. No device migration was observed in any patient, and 100% patient tolerability was achieved. Safety data for CG-100 showed 0% mortality (compared to 1.3% in patients with Stoma), 3% anastomotic leak rate (compared to 6.3% in patients with stoma), and 3% device-related adverse events graded Clavien-Dindo 3–5 (compared to 22.1% in patients with stoma). None of the Colospan&#39;s patients necessitated a permanent stoma as opposed to 23.5% in the patients with a temporary stoma.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Strategic Synergy</b></p><p xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">&#34;By combining resources, Galmed plans to deliver a clinically compelling and economically meaningful tool to reshape the standard of care for colorectal resection patients worldwide,</i>&#34; said<i xmlns="http://www.w3.org/1999/xhtml"> <b xmlns="http://www.w3.org/1999/xhtml">Allen Baharaff, Co-founder and Chief Executive Officer of Galmed</b>. &#34;The acquisition of Colospan aligns with our long-term strategic focus which remains the GI space. We strongly believe that CG-100 together with the advancement of our Ph 3 ready lead drug candidate, Aramchol, for GI related oncology indications will establish Galmed as a specialty GI medtech and biopharmaceutical platform.&#34;</i></p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">Mr. Baharaff continued</i></b><i xmlns="http://www.w3.org/1999/xhtml">: &#34;While the original terms of the acquisition contained an immediate dilutive payment in ordinary shares of $2.0 million, in order to prevent the immediate dilutive impact on Galmed shareholders, we worked together with Colospan&#39;s Board and lead investors to reach a preferred agreement: an additional cash payment of $800K (made possible by our solid cash balance of $15.6 million as of March 31, 2026) and a transparent, risk-mitigated earnout of $2.0 million on net sales, commencing in Q3 2027.&#34;</i></p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">ABOUT GALMED PHARMACEUTICALS LTD.</b></p><p xmlns="http://www.w3.org/1999/xhtml">Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/GLMD">GLMD</a>) is an Israel-based biopharmaceutical company headquartered in Ramat Gan, with a growing focus on gastrointestinal and oncological innovation. Galmed&#39;s flagship asset, Aramchol, is a first-in-class synthetic fatty acid-bile acid conjugate molecule under evaluation across liver disease and oncological indications, including GI cancers. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.galmedpharma.com/" target="_blank" rel="nofollow">www.galmedpharma.com</a>.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">ABOUT COLOSPAN LTD.</b></p><p xmlns="http://www.w3.org/1999/xhtml">Colospan Ltd. is a commercial-stage medical device company headquartered in Kfar Saba, Israel. Its flagship product, CG-100, is an intraluminal bypass device designed to protect colorectal anastomoses and reduce the need for diverting stomas, offering a less invasive alternative to standard surgical practice. CG-100 was granted FDA Breakthrough Device Designation, is CE marked under the EU Medical Device Regulation, and is approved for investigational use in the United States under an FDA approved IDE. The device is not approved for commercial use in the US. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.colospan.com/" target="_blank" rel="nofollow">www.colospan.com</a>.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">FORWARD-LOOKING STATEMENTS</b></p><p xmlns="http://www.w3.org/1999/xhtml">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to anticipated or expected events, activities, trends, or results as of the date they are made, including statements regarding the expected benefits of the acquisition. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those expressed or implied.</p><p xmlns="http://www.w3.org/1999/xhtml">Factors that could cause differences include, but are not limited to Galmed&#39;s inability to recognize the anticipated benefits of the acquisition of Colospan; expectations with respect to future performance and growth of Colospan; Galmed and Colospan&#39;s ability to execute their business plans and strategy and to receive regulatory approvals; potential litigation involving the parties; changes in domestic and foreign business, market, financial, political and legal conditions; market adoption and pricing barriers; intellectual property enforcement or infringement claims; manufacturing and supply chain constraints; intense industry competition; the ability to maintain listing on the Nasdaq Capital Market; geopolitical events, including the security situation in Israel; regulatory changes; access to additional financing; and other risks and uncertainties indicated from time to time in filings with the SEC by Galmed Additional risks relating to Colospan&#39;s product and its strategy are detailed in a report on Form 6-K filed by Galmed with the SEC on June 8, 2026 and risks associated with Galmed are detailed in Galmed&#39;s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on March 31, 2026 under the heading &#34;Risk Factors.&#34; Galmed undertakes no obligation to publicly update or revise any forward-looking statements to reflect new information, change in expectations, subsequent events, or otherwise, except as required by law. </p><p xmlns="http://www.w3.org/1999/xhtml"> Logo: <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg" target="_blank" rel="nofollow">https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg</a></p><p xmlns="http://www.w3.org/1999/xhtml"> </p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=IO88572&amp;sd=2026-06-22"></img> View original content:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-ltd-announces-restructured-acquisition-terms-for-colospan-ltd-prioritizing-cg-100-european-commercialization-and-shareholder-value-protection-and-consummation-of-acquisition-302806225.html" target="_blank">https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-ltd-announces-restructured-acquisition-terms-for-colospan-ltd-prioritizing-cg-100-european-commercialization-and-shareholder-value-protection-and-consummation-of-acquisition-302806225.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE Galmed Pharmaceuticals Ltd.</p>

Galmed Pharmaceuticals updated the Colospan acquisition terms, shifting to $0.8 million cash and a capped $2.0 million earnout starting in Q3 2027, reducing immediate dilution. The deal supports a pan-European launch of CG-100, a minimally invasive device with CE MDR clearance and a dedicated German reimbursement OPS code, with 97 patients treated and strong safety data across four trials. Galmed also plans to submit real-world CG-100 data to the FDA to support its pivotal study, potentially accelerating near-term revenue in 2026-27.

galmed-pharmaceuticals-ltd-announces-restructured-acquisition-terms-for-colospan-ltd-prioritizing-cg-100-european-commercialization-and-shareholder-value-protection-and-consummation-of-acquisition

Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

M&A

Related News